PharmacyCodes



MAP en es it fr

Categorie

MAP Les marques, MAP Analogs

MAP Les marques melange

  • Bronchyl Syrup (alcohol anhydrous + beechwood creosote + cocillana + eucalyptus + guaiacol oleate + ipecac + lobelia inflata + menthol + myroxylon balsamum + theophylline + white pine)
  • Choledyl Expectorant Elixir (guaifenesin + oxtriphylline)
  • Diuerb tab (oil of fleabane + theophylline + urea)
  • IDM Expectorant tab (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • IDM tab (potassium iodide + pyrilamine maleate + theophylline)
  • PMS-Oxtriphylline Elixir (alcohol anhydrous + oxtriphylline)
  • Pulmo Septol Sirop (beechwood creosote + cocillana + eucalyptus oil + guaiacol + ipecac + lobelia inflata + myroxylon balsamum + theophylline + white pine)
  • Ratio-theo-bronc (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • Tedral tab (l-ephedrine hydrochloride + phenobarbital + theophylline)
  • Theophylline 0.8mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 0.8mg/ml in 5% dextrose inj (dextrose + theophylline)
  • Theophylline 1.6mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 4mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline rougier elixir (alcohol anhydrous + theophylline)

    • MAP Formule chimique

    C7H8N4O2

    MAP RX lien

    http://www.rxlist.com/cgi/generic/theosr.htm

    MAP FDA fiche

    MAP FDA

    MAP msds (fiche de securite des materiaux)

    MAP MSDS

    MAP Synthese de reference

    Traube, Ber. 33, (1940)

    MAP Poids moleculaire

    180.164 g/mol

    MAP Point de fusion

    272 oC

    MAP H2O Solubilite

    1-5 g / L

    MAP Etat

    Solid

    MAP LogP

    -0.773

    MAP Formes pharmaceutiques

    Capsule (libération prolongée); Elixir; Liquid; Tablet; Tablet (libération prolongée)

    MAP Indication

    Pour le traitement des symptômes et l'obstruction bronchique réversible associé à l'asthme chronique et d'autres maladies pulmonaires chroniques, telles que l'emphysème et la bronchite chronique.

    MAP Pharmacologie

    Théophylline, un dérivé de la xanthine chimiquement semblable à la caféine et la théobromine, est utilisé pour traiter l'asthme et le bronchospasme. La théophylline possède deux actions distinctes dans les voies respiratoires des patients atteints réversibles (Asthmatiques) obstruction; relaxation des muscles lisses (ie, une bronchodilatation) et la suppression de la réponse des voies respiratoires aux stimuli (ie, non bronchodilatateur effets prophylactiques).

    MAP Absorption

    La théophylline est rapidement et complètement absorbé après administration orale en solution ou à libération immédiate sous forme solide dose orale.

    MAP Toxicite

    Les symptômes de surdose comprennent des convulsions, des arythmies et des effets gastro-intestinaux.

    MAP Information pour les patients

    Immediate Release Products

    The patient (or parent/care giver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heart beat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their clinician if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another clinician and a new medication or discontinues a previously prescribed medication. Patients should be instructed to inform all clinicians involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their clinician. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.

    Extended-Release Capsules

    This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    The physician should reinforce the importance of taking only the prescribed dose and the time interval between doses. As with any controlled-release theophylline product, the patient should alert the physician of symptoms occur repeatedly, especially near the end of the dosing interval.

    When prescribing administration by the sprinkle method, details of the proper technique should be explained to patient

    Patients should be informed of the need to take this drug in the fasting state, and that drug administration should be 1 hour before or 2 hours after meals.

    MAP Organismes affectes

    Les humains et autres mammifères